We are live on !
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
Turnover
44%
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter Est. Return
-11.22%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$192M
AUM Growth
-$269M
(-58%)
Cap. Flow
-$30M
Cap. Flow % of AUM
Cap. Flow %
-15.64%
Top 10 Holdings %
Top 10 Hldgs %
57.46%
Holding
50
New
8
Increased
10
Reduced
11
Closed
17
Avg Time Held
Equity + Options
1
year
Top 10 Avg Time Held
Equity + Options
0.2
years
Top 20 Avg Time Held
Equity + Options
0.6
years
Avg Time Held Equity only
1.1
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics
HZNP
|
+$9.47M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$5.89M |
| 3 |
MRTX
Mirati Therapeutics
MRTX
|
+$5.72M |
| 4 |
SGEN
Seagen
SGEN
|
+$5.04M |
| 5 |
Axsome Therapeutics
AXSM
|
+$4.13M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SRRA
Sierra Oncology
SRRA
|
+$10.4M |
| 2 |
Celldex Therapeutics
CLDX
|
+$8.71M |
| 3 |
Ascendis Pharma
ASND
|
+$6.13M |
| 4 |
Cogent Biosciences
COGT
|
+$5.46M |
| 5 |
Bicycle Therapeutics
BCYC
|
+$4.39M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 75.76% |
| 2 | Miscellaneous | 24.24% |
| 3 | Financials | 0% |
Similar funds
AFS
E
Ghost Tree Capital's Q2 2022 Portfolio in Review
As of Q2 2022, Ghost Tree Capital held 50 positions worth $192M, down 58% from $461M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Ghost Tree Capital withdrew a net $30M in Q2 2022, closing 17 positions and reducing 11 holdings. Its most notable exit was Sierra Oncology, an estimated $10.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 43% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Ghost Tree Capital opened a new position in Horizon Therapeutics worth $7.98M.
- Ghost Tree Capital's largest Q2 2022 buy was Horizon Therapeutics: 100,000 shares worth $7.98M.
- Ghost Tree Capital added most to Sarepta Therapeutics in Q2 2022, an estimated $5.89M increase.
- Ghost Tree Capital's biggest Q2 2022 reduction was Ascendis Pharma, cutting an estimated $6.13M.
- Ghost Tree Capital fully exited Sierra Oncology in Q2 2022, selling an estimated $10.4M.
- Ghost Tree Capital's ten largest holdings make up 57% of its $192M portfolio in Q2 2022.
- Ghost Tree Capital opened 8 new positions and closed 17 in Q2 2022.
- Ghost Tree Capital's portfolio value fell 58% quarter-over-quarter to $192M.
Based on Ghost Tree Capital's 13F filing for Q2 2022, filed 15 Aug 2022.